Glucose excipients are commonly used in pharmaceutical and dental applications. They act as filler, binder and diluent in tablets and other solid dosage forms. Glucose excipients improve the solubility and stability of drugs while enhancing patient compliance due to their ability to mask bitter tastes. The global Glucose Excipient Market is estimated to be valued at US$ 5,863.3 Mn in 2023 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Growth in Biosimilars Market Boosts Demand for Glucose Excipients
One of the major trends driving the growth of the glucose excipient market is the rising demand from the biosimilars sector. Biosimilars are generic versions of biologics and contain glucose excipients as fillers and stabilizers. The global biosimilars market is growing at a rapid pace due to the expiration of patents of major biologics and lower costs of biosimilars. According to Allied Market Research, the global biosimilars market size was valued at $5.8 billion in 2019 and is projected to reach $35 billion by 2027, growing at a CAGR of 24.5% during the forecast period. The increasing uptake of biosimilars is directly boosting the demand for glucose excipients used in their manufacturing process. This rising demand from biosimilars will support market growth over the forecast period.
Segment Analysis
The global glucose excipient market is dominated by the tablet segment, which accounted for the largest revenue share in 2023. Glucose is commonly used as an excipient in tablet formulations owing to its ability to act as a binder to hold ingredients together and provide structure to tablets. Tablets also continue to be one of the most popular and convenient dosage forms for drug delivery.
Key Takeaways
The global glucose excipient market is expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis: Europe accounted for the largest share of the global glucose excipient market in 2023. This can be attributed to the presence of major pharmaceutical companies and excipient manufacturers in countries like Germany, France, and Italy. The growth of the European market is further supported by the rising pharmaceutical R&D activities and drug development pipelines in the region.
Key players operating in the glucose excipient market include Polident D.O.O., Amt Medical SRL, Ivoclar Vivadent, VITA Zahnfabrik H. Rauter GmbH & Co. KG., Merz Dental GmbH, 3D Diagnostix Inc., Medical Precision Implants, FSM Dental Medikal Mak. San. Tic. Ltd. Sti., Yamahachi Dental Mfg., Co., Glidewell, Anthogyr SAS, Dentsply Sirona, 3Shape, Zimmer Biomet, SprintRay Inc., Thommen Medical AG, Institut Straumann AG, and Henry Schein, Inc. Polident D.O.O. and Amt Medical SRL are some of the leading manufacturers of glucose excipients.
No comments:
Post a Comment